These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20673734)

  • 41. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
    Abraham A; Alsultan A; Jeng M; Rodriguez-Galindo C; Campbell PK
    Pediatr Blood Cancer; 2013 Jun; 60(6):E19-22. PubMed ID: 23255383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
    Choi J; Foss F
    Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
    Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
    Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.
    Thomas X; Le Jeune C
    Expert Opin Pharmacother; 2016 Dec; 17(17):2319-2330. PubMed ID: 27759440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.
    Waud WR; Gilbert KS; Parker WB; Secrist JA
    Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):826-38. PubMed ID: 22060549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
    Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
    J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nelarabine.
    Gandhi V; Keating MJ; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Jan; 5(1):17-8. PubMed ID: 16485343
    [No Abstract]   [Full Text] [Related]  

  • 48. Clofarabine: in pediatric patients with acute lymphoblastic leukemia.
    Curran MP; Perry CM
    Paediatr Drugs; 2005; 7(4):259-64; discussion 265-6. PubMed ID: 16117562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clofarabine in the treatment of poor risk acute myeloid leukaemia.
    Krawczyk J; Ansar N; Swords R; Murphy T; MacDonagh B; Meenaghan T; Hayden P; Hayad A; Murray M; O'Dwyer M
    Hematol Oncol; 2010 Sep; 28(3):118-23. PubMed ID: 19768694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia.
    Williams JS; Mufti GJ; Powell S; Salisbury JR; Higgins EM
    Clin Exp Dermatol; 2007 Jul; 32(4):395-7. PubMed ID: 17376213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nucleosides as anticancer agents: from concept to the clinic.
    Secrist JA
    Nucleic Acids Symp Ser (Oxf); 2005; (49):15-6. PubMed ID: 17150610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A tale of two drugs.
    Nat Rev Drug Discov; 2006 Oct; 5(10):803. PubMed ID: 17078168
    [No Abstract]   [Full Text] [Related]  

  • 53. Mechanisms of anti-cancer action and pharmacology of clofarabine.
    Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
    Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nelarabine use in leukemias.
    Kisor DF
    Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clofarabine in leukemia.
    Ghanem H; Jabbour E; Faderl S; Ghandhi V; Plunkett W; Kantarjian H
    Expert Rev Hematol; 2010 Feb; 3(1):15-22. PubMed ID: 21082931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of hemodialysis on the plasma levels of clofarabine.
    Steinherz PG; Shukla N; Kobos R; Latcha S
    Pediatr Blood Cancer; 2010 Jul; 55(1):196-8. PubMed ID: 20232428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clofarabine as a bridge to hematopoietic stem cell transplant.
    Thomas CM; Ippoliti C; Roboz GJ; Feldman E; Savva D; James S; van Besien K
    Leuk Lymphoma; 2017 Jan; 58(1):230-232. PubMed ID: 27240704
    [No Abstract]   [Full Text] [Related]  

  • 59. Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia.
    Musto P; Ferrara F
    Cancer; 2008 Oct; 113(8):1995-8. PubMed ID: 18780321
    [No Abstract]   [Full Text] [Related]  

  • 60. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.
    Bhamidipati PK; Jabbour E; Konoplev S; Estrov Z; Cortes J; Daver N
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):342-6. PubMed ID: 23246163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.